June 29 - July 2, 2016 Barcelona
![]() |
![]() |
![]() |
![]() |
2-PD | Response to chemotherapy and prognosis in metastatic colorectal cancer with deficient mismatch repair | ALEXANDRA ALEX | ![]() |
![]() |
|||
2-P | Suppression of Lipocalin-2 promotes the Epithelial-to-Mesenchymal Transition in human colorectal cancer cells | Se Lim Kim | ![]() |
![]() |
|||
2-RM | Molecular characterization of gastrointestinal stromal tumours GISTs : The experience ofHassan IIUniversity Hospital-Fez; Morocco | doumbia hamidou dioba | ![]() |
![]() |
|||
3-P | EXTENDED MUTATIONAL PROFILING FOR METASTATIC COLORECTAL CANCER (CRC): BEYOND RAS MOLECULAR SPECTRUM OF KRAS-NRAS-BRAF AND PI3K IN CANCER COLORECTAL. | SILVINA OTERO | ![]() |
![]() |
|||
3-PD | Analysis of single-nucleotide polymorphisms (SNPs) in thephase 3 CORRECT trial of regorafenib vs placebo in patientswith metastatic colorectal cancer (mCRC) | Dieter Lambrechts | ![]() |
![]() |
|||
3-O | Long term follow up in the SCALOP-1 trial: a randomised Phase II trial of induction chemotherapy followed by gemcitabine or capecitabine based chemoradiotherapy for locally advanced non-metastatic pancreatic cancer | Somnath Mukherjee | ![]() |
![]() |
|||
4-O | Effects of nal-IRI (MM-398) 5-Fluorouracil on Quality of Life (QoL) in NAPOLI-1:A Phase 3 Study in Patients With Metastatic Pancreatic DuctalAdenocarcinoma (mPDAC) Previously Treated With Gemcitabine-Based Therapy | Richard Hubner | ![]() |
![]() |
|||
4-PD | Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study | Federica Marmorino | ![]() |
![]() |
|||
5-PD | Clinical validation of response and resistance factor candidates to targeted therapy in gastric cancer | Florian Lordick | ![]() |
![]() |
|||
5-O | Comparative molecular analyses of esophageal adenocarcinoma, esophageal squamous cell carcinoma, and gastric adenocarcinoma - and impact on outcome | Joanne Xiu | ![]() |
![]() |
|||
6-PD | Final Analysis of Stage 1 Data From a Randomized Phase 2 Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients, Utilizing Ventana Companion Diagnostic Assay | Joseph Takacs | ![]() |
![]() |
|||
6-P | Hypermethylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A promoter regions in patients with colorectal cancer | Denis Kutilin | ![]() |
![]() |
|||
7-O | Biomarker Analyses of Second-Line Ramucirumab in Patients With AdvancedGastric Cancer From RAINBOW, a Global, Randomized, Double-Blind, Phase 3 Study | Eric Van Cutsem | ![]() |
![]() |
|||
8-RM | SURGICAL EMERGENCIES IN COLORECTAL MALIGNANCIES - PATIENT PROFILE ANALYSIS | Bharathi Mohan Thangasamy | ![]() |
![]() |
|||
9-O | NETTER-1 Phase III: Efficacy and Safety Results in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate | ANNALISA ZANUSO | ![]() |
![]() |
|||
9-PD | Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of ed elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies. | Mariaelena Casagrande | ![]() |
![]() |
|||
11-RM | Safety and Efficacy of Biweekly Cetuximab Based Chemotherapy for Patients with Metastatic Colorectal Cancer | kamel ahmed | ![]() |
![]() |
|||
11-P | Tumor budding is associated with low expression of miRNA-148a and miRNA-625-3p in colorectal cancer | Edita Baltruskeviciene | ![]() |
![]() |
|||
11-O | Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO | Carlotta Antoniotti | ![]() |
![]() |
|||
12-P | CCL2 expression is correlated with Snail expression and affects the prognosis of patients with gastric cancer | Jia Zhang | ![]() |
![]() |
|||
13-P | Prognostic Significance of cyclin D1 and p21(WAF1/CIP1) in Gastric Cancer | Vasiliki Michalaki | ![]() |
![]() |
|||
13-O | A NEW NOMOGRAM FOR ESTIMATING 12-WEEKS SURVIVAL IN PATIENTS (PTS) WITH CHEMOREFRACTORY METASTATIC COLORECTAL CANCER (mCRC) | Filippo Pietrantonio | ![]() |
![]() |
|||
13-PD | Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE) | Takayuki Yoshino | ![]() |
![]() |
|||
14-P | Are RHOA, CSNK1A1, DVL2, FZD8 and LRP5 Genes Novel Biomarkers in theConversion from Intestinal Metaplasia to Gastric Cancer? | Ufuk Demirci | ![]() |
![]() |
|||
14-O | Evaluation of depth of response within a volumetric model in patients withmetastatic colorectal cancer: results of the SIRFLOX study | Farah Dunlop | ![]() |
![]() |
|||
15-O | Association Between Depth of Response and Survival Outcomes inRASWild-Type Patients With Metastatic Colorectal Cancer Receiving First-LineFOLFOX or FOLFIRI Plus Cetuximab Once Every 2 Weeks In The APEC Study | Gino Randazzo | ![]() |
![]() |
|||
15-RM | Clinicopathological, epidemiological and outcome of treatment of advanced gastric cancer in Egypt: single institution experience | Ahmed Gaballah | ![]() |
![]() |
|||
15-P | Detection of genes &1089;opy number variation as predictive markers for metastases in patients with gastric cancer | Denis Kutilin | ![]() |
![]() |
|||
16-P | Circulating mRNA expression of CD133, SNAIL, ZEB1 and ZHX as biomarkers in gastric and esophageal cancer. | Federico Longo | ![]() |
![]() |
|||
16-PD | Current results of a Phase I study of DKN-01 in combination with paclitaxel (P)in patients (pts) with advanced DKK1 esophageal cancer (EC) orgastro-esophageal junction tumors (GEJ) | Cynthia Sirard | ![]() |
![]() |
|||
16-RM | Prognostic factors and assessment of postoperative chemoradiotherapy in gastric cancer | Mghirbi Fahmi | ![]() |
![]() |
|||
16-O | A prognostic marker for colorectal cancer: combining analyses of ploidy and stroma | Susan Fotheringham | ![]() |
![]() |
|||
17-P | ANALYSIS OF microRNA EXPRESSION IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS | Sandra Jimena Vega Neira | ![]() |
![]() |
|||
17-PD | A population-based study of gastric adenocarcinoma in Central Norway 2001 - 2011 | Erling A Bringeland | ![]() |
![]() |
|||
17-RM | Systemic chemotherapy in Advanced gastric carcinoma: A comparison of DCF versus CF; versus ECF regimens in clinical setting.A reterospective study | PRAMILA KUMARI | ![]() |
![]() |
|||
18-O | Clinical application of targeted next generation sequencing for colorectal cancer patients: a multicentric Belgian experience | Nicky DHaene | ![]() |
![]() |
|||
18-RM | PRECISE SELECTION OF METASTATIC GASTRIC CANCER PATIENTS FOR FIRST LINE, DOCETAXEL BASED CHEMOTHERAPY: A RETROSPECTIVE STUDY. | PRAVEEN KUMAR KHATRI | ![]() |
![]() |
|||
18-PD | Risk Factors for Metachronous Gastric Carcinoma Development After Endoscopic Resection of Gastric Dysplasia ; Retrospective, Single Center Study | Hee Seok Moon | ![]() |
![]() |
|||
19-PD | ARQ 087, an Oral Pan- Fibroblast Growth Factor Receptor (FGFR) Inhibitor, in Patients with Advanced and/or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) | Michele Droz | ![]() |
![]() |
|||
19-P | Use of serum levels of cytokine TGF &946;1 in detection of Hepatocellular carcinoma in patients with chronic liver disease | Amila Mehmedovic | ![]() |
![]() |
|||
21-O | Tailored strategy for locally-advanced rectal carcinoma according to the tumor response to induction trichemotherapy: preliminary results of the French phase II multicenter GRECCAR4 trial. | philippe rouanet | ![]() |
![]() |
|||
21-PD | A Single Centre Experience of the prognostic variables in Hepatocellular carcinoma (HCC) patients treated with Transarterial Chemoembolization | Preetha Aravind | ![]() |
![]() |
|||
22-P | Predictive biomarkers of pathologic response to preoperative chemoradiotherapy in locally advanced rectal cancer | Radmila Jankovic | ![]() |
![]() |
|||
22-O | A Multi-Institutional Phase 2 Study of Single Agent Nivolumab in Previously Treated Metastatic Squamous Cell Carcinoma of the Anal Canal (SCCA). | Amir Mehdizadeh | ![]() |
![]() |
|||
22-PD | FOLFOXIRI as primary treatment for locally advanced unresectable pancreatic cancer (LAPC): a prospective study | Caterina Vivaldi | ![]() |
![]() |
|||
23-PD | Safety Across Subgroups in NAPOLI-1: a Phase 3 Study of nal-IRI (MM-398) 5-Fluorouracil and Leucovorin Versus 5-Fluorouracil and Leucovorin in MetastaticPancreatic Cancer Previously Treated With Gemcitabine-Based Therapy | Li-Tzong Chen | ![]() |
![]() |
|||
24-PD | Retrospective Analysis of Quality of life and early tumour Shrinkage During First-line FOlFOX4 Panitumumab in RAS Wild-type metastatic Colorectal Carcinoma | Daniel Booth | ![]() |
![]() |
|||
24-P | Carcinoembryonic antigen (CEA) and the carcinoma antigen 19-9 (CA 19-9) together in early diagnosis of Stage I-II colorectal adenocarcinoma. A case-control study | Franco Lumachi | ![]() |
![]() |
|||
25-RM | Chemoradiation for Unresectable Gall Bladder Cancer: Regional cancer centre study. | PRAMILA KUMARI | ![]() |
![]() |
|||
25-PD | RECOURSE Trial: Impact of Adverse Events on Quality of Life and Duration of Trifluridine and Tipiracil (TAS-102) Treatment | Josep Tabernero | ![]() |
![]() |
|||
25-O | First-Line FOLFOX-4 Cetuximab in Patients With RASWild-Type Metastatic Colorectal Cancer: The Open-Label,Randomized Phase 3 TAILOR Trial | Gino Randazzo | ![]() |
![]() |
|||
26-RM | IN GASTROINTESTINAL CANCERS, PATIENTS PERSPECTIVES ON PALLIATIVE CHEMOTHERAPY : A PROSPECTIVE STUDY | PRAVEEN KUMAR KHATRI | ![]() |
![]() |
|||
26-O | Combination of Encorafenib and Cetuximab With or Without Alpelisib in Patients With Advanced BRAF-Mutant (BRAFm)Colorectal Cancer: Phase 2 Results | Josep Tabernero | ![]() |
![]() |
|||
26-P | Assessment of lymph nodes for micrometastasis in high risk patients with colorectal cancer | Gulrukh Botiralieva | ![]() |
![]() |
|||
26-PD | Survival Outcomes in Patients with RAS Wild-type metastatic Colorectal Cancer Classified by Khne Prognostic Category and BRAF mutation Status: Retrospective Analysis of the PRIME Study | Dan Booth | ![]() |
![]() |
|||
27-P | Cancer stem cells marker CD44 and NOTCH activation predict unfavorable prognosis in metastatic colon cancer patients treated with anti VEGF-therapy | Francesca Negri | ![]() |
![]() |
|||
28-PD | Retrospective Analysis of Impact of Khne Prognostic Category and BRAF mutation Status on Survival in Patients with RAS Wild-type metastatic Colorectal Cancer treated With Second-line FOlFIRI With/Without Panitumumab | Daniel Booth | ![]() |
![]() |
|||
28-RM | Gemcitabine in Combination With capcitabine Compared With Gemcitabine combined with Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer | PRAVEEN KUMAR KHATRI | ![]() |
![]() |
|||
28-P | Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG) | john souglakos | ![]() |
![]() |
|||
29-RM | Outcome of continuous infusion of low dose gemcitabine in locally advanced and metastatic pancreatic carcinoma | Salah Mabrouk Khallaf | ![]() |
![]() |
|||
30-RM | Phase III study of Capecitabine and Oxaliplatin versus 5-fluorouracil in Neoadjuvant Chemoradiation for Locally Advanced Rectal Carcinoma | Marwa Khalaf | ![]() |
![]() |
|||
30-P | Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer | Vincenzo Ricci | ![]() |
![]() |
|||
31-PD | An exploratory Study-level meta-Analysis Assessing the Impact of early tumour Shrinkage on Overall Survival in Patients with RAS Wild-type metastatic Colorectal Cancer Receiving First-line treatment in three Randomised Panitumumab trials | Daniel Booth | ![]() |
![]() |
|||
31-RM | Preoperative short-course chemoradiation with consolidation with consolidation chemotherapy and delayed surgery in locally advanced rectal cancer( T3-T4 or N ) | Sarvazad Sotoudhe | ![]() |
![]() |
|||
32-RM | Neoadjuvant Chemoradiotherapy and Chemotherapy in Patients with Locally Advanced Rectal Cancer | Marwa Khalaf | ![]() |
![]() |
|||
32-PD | Evolution of efficacy and safety of cetuximab with the determination of RAS status in Metastatic Colorectal Cancer (mCRC) elderly patients | Fanny MARHUENDA | ![]() |
![]() |
|||
32-P | A complete blood count as a prognostic marker in patients with metastatic colorectal cancer (mCRC). | Magdalena Krakowska | ![]() |
![]() |
|||
33-RM | Rectal Cancer in Patients Younger than 40 at AUBMC: Tumor Characteristics and Com- parative Survival and Disease Free Survival | Ali Shamseddine | ![]() |
![]() |
|||
34-PD | Heterogeneity in the first-line treatment of patients with advanced or metastatic gastric cancer in the U.S. | Thomas Abrams | ![]() |
![]() |
|||
35-P | Simultaneous carcinoembryonic antigen (CEA), carcinoma antigen 19-9 (CA 19-9) and 125 (CA-125) measurement in patients with STAGE IA-IB gastric cancer. A case-control study | Franco Lumachi | ![]() |
![]() |
|||
35-PD | Efficacy and safety of second-line irinotecan based chemotherapy in early relapse patients with gastric cancer after adjuvant chemotherapy: Exploratory subgroup analysis of TRICS trial | Kazuhiro Nishikawa | ![]() |
![]() |
|||
36-P | Long Interspersed Nuclear Element (LINE)-1 Methylation Level as a Molecular Marker of Early Gastric Cancer | Soo A Choi | ![]() |
![]() |
|||
36-PD | Maintenance chemotherapy or Observation alone following Gemcitabine-Platinum combination palliative chemotherapy in locally advanced and/or metastatic gallbladder cancer - a single tertiary care centre experience in South Asia | Rakesh pinninti | ![]() |
![]() |
|||
37-RM | Neo-adjuvant FOLFIRINOX in borderline resectable/locally advanced pancreatic adenocarcinoma | Ali Shamseddine | ![]() |
![]() |
|||
37-P | The Role of Carcino-embryonic Antigen Testing among Western Patients with Resected Gastric Cancer | Erin Greenleaf | ![]() |
![]() |
|||
38-RM | Modified GTX second-line therapy in pancreatic adenocarcinoma | Ali Shamseddine | ![]() |
![]() |
|||
39-PD | Role of adjuvant radiotherapy following neo-adjuvant chemotherapy (NACT) and surgery in oesophageal cancer a multi-centre retrospective cohort study | Somnath Mukherjee | ![]() |
![]() |
|||
39-P | 5-FU DEGRADATION RATE IN PATIENTS WITH RECURRENT GASTROINTESTINAL CANCER TREATED WITH METRONOMIC CAPECITABINE | Michela Roberto | ![]() |
![]() |
|||
40-PD | Risk assessment for gastrointestinal cancers in patients with family history of gastrointestinal cancer: Multi-center interim analysis study in the Republic of Korea | Joo Won Chung | ![]() |
![]() |
|||
41-P | IKAROS: a potential prognostic marker in pancreatic ductal adenocarcinoma. | Marlid Cruz | ![]() |
![]() |
|||
41-RM | Risk of selected gastrointestinal toxicities in cancer patients treated with Pazopanib; a systematic review and meta-analysis | lamiaa abdallah | ![]() |
![]() |
|||
42-P | The genetic profile of pancreatic circulating tumor cells | Maria Papadimitriou | ![]() |
![]() |
|||
43-P | Significance of bcl-2 in rectal cancer recurrences | Gulrukh Botiralieva | ![]() |
![]() |
|||
43-RM | Eruptive seborrheic keratosis (ESK) and its association with gastrointestinal cancer (GIC). A case-control study and meta-analysis | Jesus Insuasty | ![]() |
![]() |
|||
45-RM | PRE-OPERATIVE DIAGNOSIS IN PANCREATIC TUMORS -REALITY OR MYTH? | Dr. Bharathi Mohan Thangasamy | ![]() |
![]() |
|||
45-P | Resistant form of helicobacter pylori in development of stomach MALT lymphoma | Makhsud Mallaev | ![]() |
![]() |
|||
47-P | Sorafenib after locoregional treatments for advanced or recurrent hepatocellular carcinoma | Catarina Ribeiro | ![]() |
![]() |
|||
48-P | Prognostic Impact of CA19-9 Level at Diagnosis in Pancreatic Adenocarcinoma: A U.S. Population Study | Katelin Mirkin | ![]() |
![]() |
|||
49-P | A population study of correlation between the treatment rate for monoclonal antibodies (Mabs) and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia | Mikhail Fedyanin | ![]() |
![]() |
|||
49-RM | Colorectal cancer in Medan Indonesia. A single centre report | Sry Widjaja | ![]() |
![]() |
|||
50-RM | Lifestyle habits and dietary patterns in gastric cancer patients in Toungoo; Myanmar | Khin Khin Nwe | ![]() |
![]() |
|||
50-P | THE PHARMACOLOGICAL COSTS OF FIRST-LINE THERAPIES IN UNSELECTED ADVANCED COLORECTAL CANCER PATIENTS: A REVIEW OF PUBLISHED PHASE III TRIALS | Jacopo Giuliani | ![]() |
![]() |
|||
51-RM | Evidence-based assessment of the burden of infection related solid tumors | Ahmed Alnagar | ![]() |
![]() |
|||
51-P | Clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI Aflibercept (FA). Preliminary results. | Carles Pericay Pijaume | ![]() |
![]() |
|||
52-RM | PANCREATIC CANCER OUR EXPERIENCE (EPIDEMIOLOGY). | Recioui Abdallah | ![]() |
![]() |
|||
53-RM | A Clinico epidemiological study of non metastatic gastrointestinal stromal tumor A prospective observational multi institutional study from Southern India | KRISHNAKUMAR RATHNAM | ![]() |
![]() |
|||
55-P | Prospective evaluation for chemotherapy-induced nausea and vomiting in colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk | Mototsugu Shimokawa | ![]() |
![]() |
|||
56-P | Outcome of Maintenance Therapy in Patients Who Achieved NED After Liver Resection for mCRC | marwan al-hajeili | ![]() |
![]() |
|||
57-P | Body Composition, beyond Body Mass Index and sarcopenia, has a major prognostic impact on patients with refractory advanced Colorectal Cancer | Camille Van Bogaert | ![]() |
![]() |
|||
59-RM | The effect of adjuvant chemotherapy folowing extended total gastrectomy for Siewerts type II adenocarcinoma of the esophagogastric junction | Ramiz Bayramov | ![]() |
![]() |
|||
61-P | Use of aflibercept in colorectal cancer patients - real world experiences in the North West | Nicola Flaum | ![]() |
![]() |
|||
63-RM | Neoadjuvant Chemotherapy for Unresectable Gall Bladder Carcinoma : Our experience | Sandeep Bhoriwal | ![]() |
![]() |
|||
63-P | Effect of age on treatment effect and tolerability of SIRT when added to mFOLFOX chemotherapy inpatients with metastatic colorectal cancer (mCRC) results from the SIRFLOX study | Farah Dunlop | ![]() |
![]() |
|||
64-P | Bevacizumab with chemodoublet as conversion-to-resectability therapy for patients with liver metastases of colorectal cancer | Marija Ristic | ![]() |
![]() |
|||
66-RM | Histological diagnosis of gastric submucosal tumors after endoscopic submucosal dissection | Olena Kuryk | ![]() |
![]() |
|||
66-P | New methods of detecting oxaliplatin-induced peripheral sensory neuropathy in colon cancer patients during adjuvant treatment with 5-fluorouracil/oxaliplatin | Joanna Szpejewska | ![]() |
![]() |
|||
68-P | Cetuximab in addition to oxaliplatin, fluouracil and radiotherapy for patients with esophageal cancer treated without surgery | Gabriella Alexandersson von Dbeln | ![]() |
![]() |
|||
69-P | Neoadjuvant chemotherapy for esophageal cancer: Comparison of DCS (DTX/CDDP/S-1) chemotherapy with FAN (5-FU/ADM/Nedaplatin) | Hideaki Shimoji | ![]() |
![]() |
|||
71-P | Clinical relevance of histologic subtypes in esophageal carcinoma treatedwith neoadjuvant chemo-radiotherapy. | Mariaiconcologia.net Saigí | ![]() |
![]() |
|||
72-P | Pattern of recurrence and efficacy of salvage therapy after relapse in locally advanced esophageal carcinoma treated with preoperative chemoradiotherapy plus surgery | MARC OLIVA | ![]() |
![]() |
|||
73-P | Non surgical management of Oesophageal cancer- a retrospective audit with 10 year follow up | Ravi Kodavatiganti | ![]() |
![]() |
|||
74-P | DISTANT OUTCOME OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE AND METASTATIC OESOPHAGEAL CANCER AFTER MULTIMODALITY TREATMENT | Luiza Serbanescu | ![]() |
![]() |
|||
76-P | Integrating CROSS style chemotherapy regime into higher doses of radiation for the radical treatment of localized oesophageal carcinoma in patients with borderline fitness. | Pei Shuen Lim | ![]() |
![]() |
|||
81-P | Phase II study of adjuvant chemotherapy with S-1 plus Oxaliplatin for gastric cancer | Lin Yang | ![]() |
![]() |
|||
82-P | Three years of metastatic gastric cancer follow up in our hospital | Marta Ferrer | ![]() |
![]() |
|||
86-P | Clinical outcome after Endoscopic Submucosal Dissection for Early Gastric Cancer of Absolute and Expanded Indication ; Retrospective Single Center Study | HYUK SOO EUN | ![]() |
![]() |
|||
87-P | A phase II study of a combination treatment of alternate-day S-1 and lentinan as first-line chemotherapy for unresectable or recurrent gastric cancer | Shigefumi Yoshino | ![]() |
![]() |
|||
92-P | PERIOPERATIVE CHEMOTHERAPY IN GASTRIC ADENOCARCINOMA- PROGNOSTIC FACTORS IDENTIFICATION | Cristiana Marques | ![]() |
![]() |
|||
93-P | IS THERE STILL A ROLE FOR ADJUVANT RADIOTHERAPY IN THE CASE OF PATIENTS WITH PRIMARY RESECTABLE GASTRIC CANCER? | Luiza Serbanescu | ![]() |
![]() |
|||
94-P | Early and long-term outcomes of gastric cancer patients treated with perioperative chemotherapy and radical surgery in a single cancer center | Paulyne Viapiana | ![]() |
![]() |
|||
97-P | Hepatic Artery Embolization (HAE) In Hepatocellular and Gastroenteropancreatic Neuroendocrine Tumors at Instituto Oncologico Nacional. Panama. | Omar Castillo-Fernandez | ![]() |
![]() |
|||
98-P | Prognostic Significance of Comorbidities in elderly patients with Hepatocellular carcinoma (HCC) treated with Transarterial Chemoembolization: A Single Centre Experience | Preetha Aravind | ![]() |
![]() |
|||
102-P | Effectiveness of TACE as bridge therapy for liver transplant in hepatocellular carcinoma | Catarina Ribeiro | ![]() |
![]() |
|||
103-P | Prognostic factors for survival in patients with advances intrahepatic cholangiocarcinoma treated with gemcitabine plus cisplatin as first line treatment | Utako Ishimoto | ![]() |
![]() |
|||
104-P | A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer | Hee Man Kim | ![]() |
![]() |
|||
105-P | Surveillance CT in patients with complete remission following curative chemoradiotherapy for Anal Cancer (Single Centre experience) | Christos Mikropoulos | ![]() |
![]() |
|||
106-P | M.D., Ph.D. | Seung Taik Kim | ![]() |
![]() |
|||
107-P | EPIDEMIOLOGY OF LYMPHOMAS INVOLVING THE GASTRO INTESTINAL TRACT : A MULTICENTRE RETROSPECTIVE STUDY FROM SOUTHERN INDIA | KRISHNAKUMAR RATHNAM | ![]() |
![]() |
|||
108-P | Role of adjuvant treatment in periampullary carcinoma | Saphalta Baghmar | ![]() |
![]() |
|||
109-P | MALT-Lymphoma - always a good prognosis? | Garcia Ana Rita | ![]() |
![]() |
|||
111-P | Correlation of Mitotic Index and Ki-67 and Their Impacts on Survival of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at Ramathibodi Hospital | THITIYA DEJTHEVAPORN | ![]() |
![]() |
|||
112-P | Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. | PRAMILA KUMARI | ![]() |
![]() |
|||
115-P | Weight Loss during 1st-line chemotherapy for upper gastrointestinal malignancies (UGI) may impact survival and access to further treatment lines | Georgios Oikonomopoulos | ![]() |
![]() |
|||
116-P | PALLIATVE THERAPY IN UNRESECTABLE ADVANCED GALL BLADDER CANCERS, A RETROSPECTIVE STUDY | PRAVEEN KUMAR KHATRI | ![]() |
![]() |
|||
117-P | Phase II study of combination chemotherapy of gemcitabine/S-1 with nafamostat mesilate for advanced unresectable pancreatic cancer: First report. | Tadashi Uwagawa | ![]() |
![]() |
|||
119-P | Chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: a retrospective cohort study | Yuta Maruki | ![]() |
![]() |
|||
120-P | Gemcitabine nab-paclitaxel as first-line chemotherapy for Japanese patients with advanced pancreatic cancer in real-world clinical practice: a retrospective study | Toshifumi Yamaguchi | ![]() |
![]() |
|||
121-P | Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer | Matthew Chau | ![]() |
![]() |
|||
122-P | Phase I study of S-1, irinotecan plus oxaliplatin combination therapy (S-IROX) for unresectable pancreatic ductal adenocarcinoma | Mitsuhito Sasaki | ![]() |
![]() |
|||
123-P | Clinical Experience of the Efficacy and Safety of two FOLFIRINOX Variants for Inoperable Pancreatic Cancer | Malcolm Buhagiar | ![]() |
![]() |
|||
124-P | FOLFIRINOX in borderline resectable pancreatic carcinoma | Esther Una Cidon | ![]() |
![]() |
|||
125-P | Gemcitabine-induced pseudocellulitis in patients with pancreatic adenocarcinoma or cholangiocarcinoma | Esther Una Cidon | ![]() |
![]() |
|||
126-P | PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma | Ori Farber | ![]() |
![]() |
|||
128-P | Outcomes with Watch-and-Wait after Pelvic Radiotherapy for Rectal Cancer in East Kent | Rakesh Raman | ![]() |
![]() |
|||
129-P | Survival rates of patients with rectal cancer in the Department for General and Abdominal surgery University Clinical Center Maribor, who underwent surgery between 2004 and 2014 | Nuhi Arslani | ![]() |
![]() |
|||
130-P | Impact of age on efficacy of neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) | German Calderillo | ![]() |
![]() |
|||
132-P | The impact of obesity on complete pathologic response to neoadjuvant chemoradiotherapy in rectal cancer patients | Consuelo Diaz | ![]() |
![]() |
|||
133-P | ASSESSMENT OF SEXUAL DYSFUNCTION IN RECTAL CANCER SURVIVORS | Joana Rodrigues | ![]() |
![]() |
|||
134-P | Parthenolide suppresses hypoxia-induced angiogenesis and epithelial-mesenchymal transition by regulating hypoxia inducible factor 1 alpha signaling in colorectal cancer | Se Lim Kim | ![]() |
![]() |
|||
135-P | The role of Angiotensin II subtype IA receptor on liver metastasis formation | YUKI SHIMIZU | ![]() |
![]() |
|||
137-P | Macrophage coculture enhanced invasion of gastric cancer cells via FOXQ1 pathway | Jia Zhang | ![]() |
![]() |
|||
138-P | Is HER2 positivity gastric cancer good prognostic sign?- our experiences | Milka Vjetica | ![]() |
![]() |
|||
139-P | Monitoring of plasma concentrations of erlotinib (ERL) after long time administration of 100mg in advanced pancreatic cancer patients | Azra Sahmanovic | ![]() |
![]() |
|||
140-P | Significant intraoperative blood loss predicts poorprognosis after hepatectomy following neoadjuvantchemotherapy for liver-only colorectal metastases | Mafalda Costa Neves | ![]() |
![]() |
|||
141-P | Treatment approaches for resectable colorectal cancer metastases in the liver exhibiting poor prognosis | Sergey Khays | ![]() |
![]() |
|||
142-P | Experience with Aflibercept as a second line chemotherapy in metastatic colorectal cancer. | Encarnación González-Flores | ![]() |
![]() |
|||
143-P | The evaluation of liver resection for colorectal cancer liver metastasis | Masaichi Ogawa | ![]() |
![]() |
|||
144-P | ANTI-EGFR MONOCLONAL ANTIBODIES AND SURGERY OF METASTASES IN THE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC) | Anna Storozhakova | ![]() |
![]() |
|||
145-P | Metastases resection following FOLFIRI-aflibercept in refractory patients to first-line chemotherapy: safety and efficacy analysis | Andres Muñoz Martín | ![]() |
![]() |
|||
146-P | Colorectal cancer patients with lung-only metastases have a favorable prognosis irrespective of treatment | Moran Gadot | ![]() |
![]() |
|||
147-P | Final analysis : Phase II trial of Irinotecan/S-1/Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC : HGCSG0902. -Comparison of administration interval in Cetuximab treatment. | Satoshi Yuki | ![]() |
![]() |
|||
148-P | RECURRENCE FREE SURVIVAL AS A PUTATIVE SURROGATE FOR OVERALL SURVIVAL IN PHASE III TRIALS OF CURATIVE-INTENT TREATMENT OF COLORECTAL LIVER METASTASES: SYSTEMATIC REVIEW | Raphael Araujo | ![]() |
![]() |
|||
149-P | Impact of Sequence of Biologic therapies on Overall Survival in Patients with RAS Wild-type metastatic Colorectal Carcinoma: An exploratory, Retrospective Pooled Analysis | Daniel Booth | ![]() |
![]() |
|||
150-P | Locoregional therapy in liver dominant metastatic colorectal cancer having failed standard drug therapy: Outcome and prognostic parameters in 133 consecutive patients | Stefan Pluntke | ![]() |
![]() |
|||
151-P | The expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in patients with colorectal adenocarcinoma and lymph node metastases | Franco Lumachi | ![]() |
![]() |
|||
152-P | Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the Glasgow Prognostic Score (GPS). | Takuto Miyagishima | ![]() |
![]() |
|||
154-P | Combined oxaliplatin, irinotecan and fluorouracil as a rescue regimen for heavily pretreated metastatic colorectal cancer (mCRC) patients | Marcela Crosara Teixeira | ![]() |
![]() |
|||
155-P | Unresectable colorectal cancer liver metastases: retrospective review and survival analysis | lourdes calera Urquizu | ![]() |
![]() |
|||
156-P | Pathologic response of liver metastases from colorectal cancer after chemotherapy and aflibercept. Initial report of 23 cases from 9 patients | Frédéric Bibeau | ![]() |
![]() |
|||
157-P | A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2) | Shigeyoshi Iwamoto | ![]() |
![]() |
|||
158-P | RADIOEMBOLIZATION (SIRT) AS A CONSOLIDATION TREATMENT IN COLORECTAL LIVER METASTASES AFTER FIRST LINE CHEMOTHERAPY: EFFICACY AND SAFETY. | SALVATORE CAPONNETTO | ![]() |
![]() |
|||
159-P | Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: a multicenter retrospective comparison study | hironaga satake | ![]() |
![]() |
|||
160-P | Impact of KRAS mutation on patterns of metastasis in a series of colorectal cancer patients | Marta Domenech Viñolas | ![]() |
![]() |
|||
161-P | 5-FU based chemotherapy with Bevacizumab in synchronous metastatic colorectal cancer patients with bleeding primary tumor | Birgit Gruenberger | ![]() |
![]() |
|||
162-P | IS RESECTION THE ONLY CHOICE FOR THE TREATMENT OFBILOBAR COLORECTAL CANCER METASTASES? | Antonio Chiappa | ![]() |
![]() |
|||
164-P | Synchronous disease does not predict long-term outcomes in patients with resected colorectal cancer liver metastases | Marcio Marques | ![]() |
![]() |
|||
165-P | Efficacy and toxicity of FOLFIRI / aflibercept in second line colorectal cancer in real life population, retrospective study. Does first line matters? | Nieves Martinez Lago | ![]() |
![]() |
|||
166-P | Re-hepatectomy is a predictor of long-term survival in patients that recur after liver resection of colorectal liver metastases | Marcio Marques | ![]() |
![]() |
|||
167-P | Cetuximab rechallenge in metastatic colorectal cancer patients | Amanda Nogueira | ![]() |
![]() |
|||
168-P | Retrospective comparison of efficacy and safety of docetaxel and weekly-paclitaxel as 2nd-line chemotherapy for patients with unresectable or recurrent esophageal cancer | Hiroshi Nakatsumi | ![]() |
![]() |
|||
169-P | Outcomes of metastatic gastroesophageal cancer patients treated with third line therapy: A 5-year retrospective analysis at a single centre | Chau Ng | ![]() |
![]() |
|||
170-P | A Biweekly S-1 and nab-paclitaxel as first-line chemotherapy in patients with unresectable or recurrent gastric cancer | Lin Yang | ![]() |
![]() |
|||
171-P | The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer. | Akitaka Makiyama | ![]() |
![]() |
|||
172-P | Intraperitoneal aerosol chemotherapy (PIPAC) is a new approach in the treatment of patients with peritoneal сarcinomatosis | Anna Utkina | ![]() |
![]() |
|||
173-P | OUTCOMES OF PALLIATIVE GASTRECTOMY IN 549 ASYMPTOMATIC PATIENTS WITH ADVANCED GASTRIC CANCER | Valentina Fanotto | ![]() |
![]() |
|||
174-P | Ramucirumab and Paclitaxel in Platinum-refractory Advanced or Metastastic Gastric or Gastroesophageal Junction Adenocarcinoma a Single Center Experience | Ursula Vogl | ![]() |
![]() |
|||
175-P | EFFECTIVENESS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA | Paulo Salamanca | ![]() |
![]() |
|||
177-P | Stereotactic Radiotherapy (SRT) versus Whole Brain Radiotherapy (WBRT) in the management of 1-3 brain metastases (BM) originating from a gastrointestinal (GI) tract malignancy. | Pei Shuen Lim | ![]() |
![]() |
|||
178-P | Capecitabine and temozolomide (CAPTEM) in patients with advancedneuroendocrine tumors: the experience of a portuguese cancer center. | Andreia Chaves | ![]() |
![]() |
|||
182-P | An experience of FOLFIRINOX chemotherapy in advanced Pancreatic Cancer | Yazan Haddadin | ![]() |
![]() |
|||
183-P | Abrogation of alcohol dehydrogenase-1B (ADH1B) expression by CD90 stromal cells supports tumor-promoting inflammation in colorectal cancer | Romain Villéger | ![]() |
![]() |
|||
185-P | Overexpression of SIRT 6 induces apoptosis in hepatocellular carcinoma mediated by Wnt/&946;-catenin signaling pathway | SOO MI KIM | ![]() |
![]() |
|||
189-P | Evaluation of short-term quality of life changes after surgery in elderly patients with colorectal cancer using the Medical Outcomes Study short form (MOS-SF-36) questionnaire | Franco Lumachi | ![]() |
![]() |
|||
192-P | Ocular toxicities with oxaliplatin continue overlooked | Esther Una Cidon | ![]() |
![]() |
|||
195-P | The impact on comorbidities in deciding the dose for the first cycle of chemotherapy | Esther Una Cidon | ![]() |
![]() |
|||
196-P | Gastrointestinal stromal tumors: Fifteen years of experience in a Portuguese Hospital Centre | Sílvia Lopes | ![]() |
![]() |
|||
197-P | INTRAOPERATIVE SENTINEL LYMPH NODE POSITIVITY BY METHYLENE BLUE DYE AND ITS ASSOCIATION WITH OTHER DISSECTED LYMPH NODE BY HISTOPATHOLOGICAL EXAMINATION IN COLORECTAL CANCER | Dr.Bharathi Mohan Thangasamy | ![]() |
![]() |
|||
199-P | Dosing first cycle of chemotherapy in colorectal cancer: is BSA used for everybody? | Esther Una Cidon | ![]() |
![]() |
|||
200-P | A Study on Response for Irreversible Electroporation of Colon Cancer Cell using Multiphoton Microscopy | Jung Min Lee | ![]() |
![]() |
|||
201-P | A Comparative Study for Effectiveness of Irreversible Electroporation Ablation according to Therapeutic Method: Colon Cancer Animal Model | Jung Min Lee | ![]() |
![]() |
|||
203-P | Assessing intratumor heterogeneity and evolutionary distance in exome sequencing of colon cancer | Ulrich Popper | ![]() |
![]() |
|||
206-P | Effects of eribulin mesilate for tumor progression and fibrosis in gastric cancer | Toru Kurata | ![]() |
![]() |
|||
207-P | Protective Effect of Ursodeoxycholic acid in the Chemotherapy Induced Mucositis : an In Vitro Animal Experiment | Jung Min Lee | ![]() |
![]() |
|||
208-P | Pre-therapy functional and body status of patients with advanced gastrointestinal cancer compared to breast cancer patients and healthy women | Katrin Stuecher | ![]() |
![]() |
|||
209-P | Maintenance BEZ235 treatment following BEZ235 and radiation treatment prolongs the therapeutic effect in colorectal cancer | Ming-Feng Wei | ![]() |
![]() |
|||
212-P | An investigation of the association between sarcopenia and post-operative morbidity and mortality in patients with gastric cancer | Stephen OBrien | ![]() |
![]() |
|||
214-P | Salvage Chemoradiotherapy for Locally Recurrent Bile Duct Cancer | Jeong Il Yu | ![]() |
![]() |
|||
216-P | Treatment of squamous cell anal cancer with IMRT and simultaneous hypofractionated boost combined with concurrent chemotherapy | Laura Diaz | ![]() |
![]() |
|||
217-P | Chemoradiotherapy with IG - VMAT & IG - IMRT to treat Squamous Anal Cancer | Peter Correa | ![]() |
![]() |
|||
222-P | Comparison of Investigator-Delineated Gross Tumor Volumes and Quality Assurance in Pancreatic Cancer: Analysis of the On-trial cases for the SCALOP Trial | SOMNATH MUKHERJEE | ![]() |
![]() |
|||
224-P | Locally advanced rectal cancer:A single institution experience | Nuria Dueñas | ![]() |
![]() |
|||
226-P | Rectal Bioelectrical impedance (REBI) as a possible screening tool for colorectal cancer (CRC) | Edelberto Mulett | ![]() |
![]() |
|||
227-P | Comparative characteristics of somatic mutations in the KRAS gene in patients with colorectal cancer the South of Russia | Denis Kutilin | ![]() |
![]() |
|||
228-P | Inhibitory effects of Lactobacillus helveticus SBT2171 on the proliferation of colorectal tumor cells and the action mechanism | Kazunobu Baba | ![]() |
![]() |
|||
229-P | An Evaluation Based on a Systematic Review of Epidemiologic Evidence of Colorectal Cancer Risk among the Alcohol Consuming Indian Population | DR ANCHAL NAVNEET MISHRA | ![]() |
![]() |
|||
230-P | Muir-Torre Syndrome diagnostic and screening. A single center experience | Elizabeth Inga | ![]() |
![]() |
|||
231-P | PHYSICAL ACTIVITY AND BARRETTS OESOPHAGUS | Sylwia Gugala | ![]() |
![]() |
|||
232-P | The value of echinococcosis in development of liver cancer. | Aziza Almanova | ![]() |
![]() |
|||
234-P | Incidence of Sarcopenia and its relationship with Body Mass Index in colorectal cancer patients. | Vasileios Alivizatos | ![]() |
![]() |
|||
235-P | HOW OFTEN DOES THE PATIENT REPEAT SCREENING COLONOSCOPY?; A STUDY FOR PERSONALIZED RECOMMENDATION OF SCREENING COLONOSCOPY INTERVAL | Jung Min Lee | ![]() |
![]() |
|||
236-P | Screening Practices of Australians Following Partial Roll-out of the National Bowel Cancer Screening Program, 2009-2012 | Louisa Flander | ![]() |
![]() |
|||
237-P | Comparison of adenoma detection by polypectomy during both insertion and withdrawal versus only withdrawal of colonoscopy: a randomized, controlled multicenter trial | Jeong-Seon Ji | ![]() |
![]() |
|||
240-P | Vitamin D levels in oesophageal and gastric cancer patients and their outcome | Subodha Thanthulage | ![]() |
![]() |
|||
242-P | MORTALITY TREND FOR HEPATOCELLULAR CARCINOMA IN ALBANIA: A HEPATITIS B VIRUS ENDEMIC AREA | Fatjona Kraja | ![]() |
![]() |
|||
243-P | Undiagnosed chronic liver disease (CLD) in patients presenting with Hepatocellular Carcinoma (HCC) | Pavlina Spiliopoulou | ![]() |
![]() |
|||
244-P | Cholangiocarcinoma: A restrospective analysis of our experience in diagnosis, prognostic factors, staging and treatment. | Elizabeth Inga | ![]() |
![]() |
|||
246-P | Survival Patterns of Stage IV Pancreatic Cancer: a Population-Based Study | Mohammed Mousa | ![]() |
![]() |
|||
247-P | Young patients under 40 age with colorectal cancer have poor survival | PRAMILA KUMARI | ![]() |
![]() |
|||
248-P | Helicobacter pylori translocation to the regional lymph nodes in patients with gastric carcinoma | Paulyne Viapiana | ![]() |
![]() |
|||
249-P | Short-term results of surgery in elderly (65 years) versus younger patients with Stage I-II colonic adenocarcinoma. A case-control study | Franco Lumachi | ![]() |
![]() |
|||
253-P | Multimodal analgesia combined with epidural anesthesia and intravenous administration of acetaminophen in perioperative management of esophagectomy using modified ERAS protocol | Takashi Ogata | ![]() |
![]() |
|||
254-P | Esophagectomy with cervical anastomosis has a greater need for intervention for dysphagia than intrathoracic anastomosis | Yaron Perry | ![]() |
![]() |
|||
257-P | Surgical treatment of patients withneuroendocrine neoplasms of the stomach | Ivan Peregorodiev | ![]() |
![]() |
|||
258-P | 5-Year Survival of Gastric Cancer Patients after Radical Surgery was Significantly Depended on Tumor Characteristics, Blood Cell Circuit, Cell Ratio Factors, Hemostasis System and Adjuvant Treatment | Oleg Kshivets | ![]() |
![]() |
|||
259-P | Laparoscopic gastrectomy: our technique, complications and long-term oncological results. | Dmytro Golub | ![]() |
![]() |
|||
260-P | Outcomes of laparoscopic and open gastrectomy for gastric cancer: a comparative analysis | Bárbara Castro | ![]() |
![]() |
|||
261-P | SURVIVAL AND DISEASE-FREE SURVIVAL IN A CONSECUTIVE MONOCENTRIC SERIES OF MORE THAN 1000 D-2 GASTRIC RESECTION FOR CANCER | Antonio Chiappa | ![]() |
![]() |
|||
262-P | Multivisceral resections for gastric cancer - Should all patients with locally-disease receive them? | Paulyne Viapiana | ![]() |
![]() |
|||
263-P | Laparoscopic versus open distal gastrectomy for gastric cancer: a single-center case-control study | Bárbara Castro | ![]() |
![]() |
|||
264-P | Is laparoscopic approach an option in resection of advanced gastric cancer? | Bárbara Castro | ![]() |
![]() |
|||
266-P | Highlight of benefits in cirrhotic patient of laparoscopic resection for malignant tumor, retrospective study with propensity score analysis | Fabien Le Roux | ![]() |
![]() |
|||
268-P | SURGICAL OUTCOMES AND STRICT FOLLOW-UP OF RETROPERITONEAL SOFT-TISSUE SARCOMA | Antonio Chiappa | ![]() |
![]() |
|||
271-P | Feasibility of neoadjuvant chemotherapy with modified FOLFOX6 (combination chemotherapy of infusional 5-FU/l-Leucovorin and intermittent oxaliplatin) with bevacizumab in patients with advanced lower rectal cancer. | Chihiro Kosugi | ![]() |
![]() |
|||
273-P | Hepatectomy followed by adjuvant chemotherapy with capecitabine plus oxaliplatin for three months for liver metastases from colorectal cancer: a multicenter phase 2 study | hironaga satake | ![]() |
![]() |
|||
277-P | A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE) | Michel Ducreux | ![]() |
![]() |
|||
278-P | Phase Ib/II study of nivolumab plus CAPIRI: Initial results of metastatic colon cancer and pancreatic adenocarcinoma patients. | Vivek Khemka | ![]() |
![]() |
|||
281-P | JAVELIN Gastric 100: phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locallyadvanced or metastatic gastric or gastro-oesophageal junction cancer | Kathryn Boothroyd | ![]() |
![]() |
|||
282-P | JAVELIN Gastric 300: phase 3 trial of avelumab (anti-PD-L1 antibody) best supportive care (BSC) vs BSC chemotherapy as third-line treatment for advanced gastric or gastro-oesophageal junction cancer | Kathryn Boothroyd | ![]() |
![]() |
|||
285-P | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Following First-Line Sorafenib (REACH-2) | Emily Cullinan | ![]() |
![]() |
|||
287-P | Nanoliposomal Irinotecan (nal-IRI)-Containing Regimens Versus nab-PaclitaxelPlus Gemcitabine as First-Line Therapy in Patients With Metastatic PancreaticAdenocarcinoma: A Randomized, Open-Label Phase 2 Study | Andrew Dean | ![]() |
![]() |
|||
288-P | Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) vs placebo, both with Nab-Paclitaxel and in pts With Previously Untreated, Hyaluronan (HA)-High, Stage IV Pancreatic Ductal Adenocarcinoma | Joseph Takacs | ![]() |
![]() |
|||
289-P | Hepatic arterial infusion chemotherapy for unresectable liver metastases of colorectal cancer: a multicenter retrospective study | Annie LIM | ![]() |
![]() |
June 29 - July 2, 2016 Barcelona
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|